Top

Journal of Radiation Oncology

Published in:

01-12-2016 | Original Research

Hypofractionated whole breast irradiation for early stage breast cancer in a large community-based physician practice

Authors: Bonnie Jerome-D’Emilia, John D’Emilia

Published in: Journal of Radiation Oncology | Issue 4/2016

Abstract

Objective

Hypofractionated whole breast irradiation has been found, in clinical trials, to be a clinically efficacious short course of treatment for patients with early stage breast cancer treated with breast-conserving surgery that is underused in the USA as compared to Canada and the UK. The purpose of this study was to examine the use of hypofractionated whole breast irradiation over time in a large, multistate privately owned, community-based radiation oncology practice in the USA.

Methods

Bivariate and multivariate analyses were used. A logistic regression model was developed to identify an association between patient, tumor and nonclinical factors, and the odds of receiving hypofractionation whole breast irradiation in a group of patients who would be appropriate for this treatment.

Results

The use of hypofractionated whole breast irradiation increased over time, but the overall rate in 2013 remained quite low at 8.7 %. Additionally, the factors associated with the use of this treatment were nonclinical in nature and included advanced age and region of the USA.

Conclusion

The use of hypofractionated whole breast irradiation has been found to be slowly increasing in the USA; however, it remains low. Additional studies are needed to evaluate the use of incentives with which to encourage the use of this cost-effective and efficacious treatment in the USA.

Centers for Medicare and Medicaid Services (2015) NHE Fact Sheet https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/nhe-fact-sheet.html. Accessed May 11, 2016

Davis K, Schoen C, Schoenbaum SC, Doty MM, Holmgren AL, Kriss JL, Shea KK (2007) Mirror, mirror on the wall: an international update on the comparative performance of American health care. The Commonwealth Fund, New York

Lallemand NC (2012) Reducing waste in health care. Health Policy Briefs, Health Aff http://www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id=82. Accessed May 11, 2016

Scott IA, Duckett SJ (2015) In search of professional consensus in defining and reducing low-value care. Med J Aust 203(4):179–181CrossRefPubMed

Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, Fisher E, Wolmark N, Deutsch M, Montague E, Saffer E (1985) Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312(11):665–673CrossRefPubMed

Jagsi R (2014) Progress and controversies: radiation therapy for invasive breast cancer. CA Cancer J Clin 64:135–152CrossRefPubMed

Chu QD, Medeiros KL, Zhou M, Peddi P, Wu XC (2016) Impact of cooperative trial and sociodemographic variation on adjuvant radiation therapy usage in elderly women (≥70 years) with stage I, estrogen receptor-positive breast cancer: analysis of the National Cancer Database. J Am Coll Surg 222(4):667–678CrossRefPubMed

Konski A, Yu JB, Freedman G, Harrison LB, Johnstone PA (2016) Radiation oncology practice: adjusting to a new reimbursement model. J Oncol Prac 12(5):e576–e583CrossRef

Hoopes DJ, Kaziska D, Chapin P, Weed D, Smith BD, Hale ER, Johnstone PA (2012) Patient preferences and physician practice patterns regarding breast radiotherapy. Int J Radiat Oncol Biol Phys 82(2):674–681CrossRefPubMed

10.

Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, Lada B, Lukka H, Perera F, Fyles A, Laukkanen E (2002) Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 94(15):1143–1150CrossRefPubMed

11.

Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W, Grimard L, Bowen J, Lukka H, Perera F (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362(6):513–520CrossRefPubMed

12.

Trialists' Group T S (2008) The UK standardisation of breast radiotherapy (START) trial a of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Onc 9(4):331–341CrossRef

13.

Foundation KF (2016) State HMO penetration rate http://kff.org/other/state-indicator/hmo-penetration-rate/?activeTab=map&currentTimeframe=0&selectedDistributions=hmo-penetration-rate&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. Accessed October 7, 2016

14.

Jerome-D’Emilia B, Begun JW (2005) Diffusion of breast conserving surgery in medical communities. Soc Sci Med 60(1):143–151CrossRefPubMed

15.

Bogart JA (2004) Hypofractionated radiotherapy for advanced non-small-cell lung cancer: is the LINAC half full? J Clin Oncol 22(5):765–768CrossRefPubMed

16.

Goldberg SL, Akard LP, Dugan MJ, Faderl S, Pecora AL (2015) Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia. J Oncol Prac 11(3):e398–e404CrossRef

17.

Haffty BG, Buchholz TA (2013) Hypofractionated breast radiation: preferred standard of care? Lancet Onc 14(11):1032–1034CrossRef

18.

Abraham JM, Jerome-D’Emilia B, Begun JW (2011) The diffusion of magnet hospital recognition. Health Care Manag Rev 36(4):306–314CrossRef

19.

Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J (2013) The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Onc 14(11):1086–1094CrossRef

20.

Mitin T, Dai Kubicky C (2015) The use of hypofractionated whole breast irradiation in treatment of patients with early-stage breast cancer in the United States. JAMA oncology 1(2):245–246CrossRefPubMed

21.

Plataniotis GA, Theofanopoulou MA, Sotiriadou K, Kyrgias G (2010) Hypofractionated radiotherapy for breast cancer patients treated by breast-conserving surgery: short-term morbidity and preliminary results. Breast Cancer 17(1):42–47CrossRefPubMed

22.

Bekelman JE, Sylwestrzak G, Barron J, Liu J, Epstein AJ, Freedman G, Malin J, Emanuel EJ (2014) Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008–2013. JAMA 312(23):2542–2550CrossRefPubMedPubMedCentral

23.

Khan AJ, Dale RG, Arthur DW, Haffty BG, Todor DA, Vicini FA (2012) Ultrashort courses of adjuvant breast radiotherapy. Cancer 118(8):1962–1970CrossRefPubMed

24.

Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, McCormick B, McQueen JR, Pierce LJ, Powell SN, Recht A (2011) Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys 81(1):59–68CrossRefPubMed

25.

Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, Chronowski GM, Dvorak T, Grade E, Hoffman KE, Kelly P (2015) Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA oncology1(7): 931–41

26.

Rajagopalan MS, Flickinger JC, Heron DE, Beriwal S (2015) Changing practice patterns for breast cancer radiation therapy with clinical pathways: an analysis of hypofractionation in a large, integrated cancer center network. Pract Radiat Oncol 5(2):63–69CrossRefPubMed

27.

United States Department of Agriculture Economic Research Service (2013) Rural urban continuum codes. http://www.ers.usda.gov/data-products/rural-urban-continuum-codes/.aspx Accessed August 25, 2016

28.

Choosing Wisely (2013) ASTRO releases list of five radiation oncology treatments to question as part of national Choosing Wisely® campaign. http://www.choosingwisely.org/astro-releases-list-of-five-radiation-oncology-treatments-to-question-as-part-of-national-choosing-wisely-campaign/ Accessed October 5, 2016

29.

StataCorp (2011) Stata statistical software: release 12. StataCorp LP, College Station, TX

30.

Wang EH, Mougalian SS, Soulos PR, Rutter CE, Evans SB, Haffty BG, Gross CP, James BY (2014) Adoption of hypofractionated whole-breast irradiation for early-stage breast cancer: a National Cancer Database analysis. Int J Radiat Oncol Biol Phys 90(5):993–1000CrossRefPubMed

31.

Page BR, Belnap T, Bowen RC, Gaffney DK, Sause WT (2013) Utilization of hypofractionated and conventional breast radiotherapy in the state of Utah. Cancer & Clin. Oncologia 2(2):34–41

32.

Hung M, Bounsanga J, Crum AB, Voss MW (2016) Will regional differences in family practice procedures impact reimbursement rates? A national study of Medicare Part B. AJMC.Com 3.16 23–29. http://www.ajmc.com/journals/ajac/2016/2016-vol4-n1/will-regional-differences-in-family-practice-procedures-impact-reimbursement-rates/P-1. Accessed on October 6, 2016

33.

Koulis TA, Phan T, Olivotto IA (2015) Hypofractionated whole breast radiotherapy: current perspectives. Breast Cancer 7:363–370PubMedPubMedCentral

34.

Jagsi R, Falchook AD, Hendrix LH, Curry H, Chen RC (2014) Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials. Int J Radiat Oncol Biol Phys 90(5):1001–1009CrossRefPubMed

35.

Hegemann NS, Guckenberger M, Belka C, Ganswindt U, Manapov F, Li M (2014) Hypofractionated radiotherapy for prostate cancer. Radiat Oncol 9(1):275CrossRefPubMedPubMedCentral

36.

Lutz ST, Chow EL, Hartsell WF, Konski AA (2007) A review of hypofractionated palliative radiotherapy. Cancer 109(8):1462–1470CrossRefPubMed

37.

Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047–1060CrossRefPubMedPubMedCentral

Title: Hypofractionated whole breast irradiation for early stage breast cancer in a large community-based physician practice
Authors: Bonnie Jerome-D’Emilia
John D’Emilia
Publication date: 01-12-2016
Publisher: Springer Berlin Heidelberg
Published in: Journal of Radiation Oncology / Issue 4/2016
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-016-0286-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2016

The impact of weight loss on setup accuracy for head and neck cancer patients in the era of image guided radiation therapy

Improving overall survival with post-mastectomy radiotherapy in a group of early-stage breast cancer: the number of negative lymph nodes sufficient to eliminate post-mastectomy radiotherapy

Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC)

Considerations in radiation therapy for pregnant women with malignancy

Erratum to: A phase II experience evaluating quality of life and survival in linac-based SBRT for prostate cancer

The impact of 3D conformal radiotherapy versus intensity-modulated radiotherapy on post-operative wound complications in soft tissue sarcomas of the extremity and chest-wall

Keynote webinar | Spotlight on antibody–drug conjugates in cancer